Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $20.29, for a total value of $253,625.00. Following the completion of the sale, the chief operating officer owned 191,641 shares of the company’s stock, valued at approximately $3,888,395.89. This represents a 6.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total value of $287,625.00.
• On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.66, for a total value of $245,750.00.
• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total value of $315,838.72.

Bicara Therapeutics Trading Down 4.6%

Shares of NASDAQ BCAX opened at $19.29 on Tuesday. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $24.25. The stock has a 50 day moving average of $21.03 and a two-hundred day moving average of $18.21. The stock has a market cap of $1.27 billion, a P/E ratio of -6.94 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, research analysts predict that Bicara Therapeutics Inc. will post -3.37 earnings per share for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Several large investors have recently modified their holdings of the stock. Janus Henderson Group PLC raised its stake in shares of Bicara Therapeutics by 26.2% during the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after purchasing an additional 692,933 shares during the last quarter. Rock Springs Capital Management LP raised its stake in shares of Bicara Therapeutics by 14.0% during the first quarter. Rock Springs Capital Management LP now owns 489,095 shares of the company’s stock worth $9,728,000 after purchasing an additional 60,000 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of Bicara Therapeutics by 16.1% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after purchasing an additional 2,447 shares during the last quarter. Orbimed Advisors LLC raised its stake in shares of Bicara Therapeutics by 219.1% during the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock worth $13,273,000 after purchasing an additional 458,200 shares during the last quarter. Finally, Siren L.L.C. raised its stake in shares of Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BCAX. Citigroup began coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. Wall Street Zen cut Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Citizens Jmp restated a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. The Goldman Sachs Group upped their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, Bank of America began coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.